Fig. 2

Secondary efficacy endpoints up to week 24 (ITT population). ACR20 response rate up to week 24 (a). ACR20, ACR50, and ACR70 response rates at week 24 (b). Mean change from baseline in DAS28-CRP up to week 24 (c). Mean change from baseline in CDAI value up to week 24 (d). Mean change from baseline in SDAI value up to week 24 (e). ACR, American College of Rheumatology; ACR20, 20% improvement according to American College of Rheumatology criteria; ACR50, 50% improvement according to American College of Rheumatology criteria; ACR70, 70% improvement according to American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score in 28 joints C-reactive protein; EU-adalimumab, European Union-approved adalimumab; ITT, intention-to-treat; SDAI, Simplified Disease Activity Index